Danger-associated molecular patterns in Alzheimer's disease.

innate immune system; microglia; neurodegeneration; neuroinflammation; Alarmins; Receptors, Pattern Recognition; Alarmins/metabolism; Alzheimer Disease/metabolism; Animals; Humans; Inflammation/pathology; Models, Biological; Molecular Targeted Therapy; Receptors, Pattern Recognition/metabolism; Alzheimer Disease; Inflammation; Immunology and Allergy; Immunology; Cell Biology

Abstract :

[en] Pathogen-associated molecular patterns (PAMPs) and endogenous "danger" signals, known as danger-associated molecular patterns (DAMPs), released from cells alert the innate immune system and activate several signal transduction pathways through interactions with the highly conserved pattern recognition receptors (PRRs). Both PAMPs and DAMPs directly induce proinflammatory cascades and trigger the formation of the inflammasome, mediating the release of cytokines. Here, we highlight the role of DAMPs, including amyloid β (Aβ), high-mobility group box 1 (HMGB1), the S100 family proteins, chromogranin A, and nucleic acids, in the innate-immune activation during the course of Alzheimer disease (AD), the most frequent neurodegenerative disorder.

Disciplines :

Neurology

Author, co-author :

Venegas, Carmen; Department of Neurodegenerative Disease and Gerontopsychiatry, University of Bonn, Bonn, Germany, and

HENEKA, Michael ; Department of Neurodegenerative Disease and Gerontopsychiatry, University of Bonn, Bonn, Germany, and michael.heneka@ukb.uni-bonn.de ; German Center for Neurodegenerative Disease, Bonn, Germany

External co-authors :

yes

Language :

English

Title :

Danger-associated molecular patterns in Alzheimer's disease.

Publication date :

January 2017

Journal title :

Journal of Leukocyte Biology

ISSN :

0741-5400

Publisher :

Federation of American Societies for Experimental Biology, England

Volume :

101

Issue :

Pages :

87 - 98

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://academic.oup.com/jleukbio/article-pdf/101/1/87/48718326/jlb0087.pdf

Funders :

Deutsche Forschungsgemeinschaft

Funding text :

This work was supported by the Deutsche Forschungsgemeinschaft (DFG) excellence pogramm “Immunosensation” and the EU Joint Programme - Neurodegenerative Disease Research (EU-JPND) consortium InCure.

Available on ORBilu :

since 08 May 2024

Statistics

Number of views

57 (0 by Unilu)

Number of downloads

0 (0 by Unilu)

More statistics

Scopus citations^®

192

Scopus citations^®
without self-citations

182

OpenCitations

143

OpenAlex citations

216

WoS citations^™

170

Bibliography

Matzinger, P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045.
Gallo, P. M., Gallucci, S. (2013) The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity. Front. Immunol. 4, 138.
Vance, R. E., Isberg, R. R., Portnoy, D. A. (2009) Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system. Cell Host Microbe 6, 10-21.
Kono, H., Rock, K. L. (2008) How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279-289.
Gasser, S., Orsulic, S., Brown, E. J., Raulet, D. H. (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186-1190.
Schaefer, L., Babelova, A., Kiss, E., Hausser, H. J., Baliova, M., Krzyzankova, M., Marsche, G., Young, M. F., Mihalik, D., Götte, M., Malle, E., Schaefer, R. M., Gröne, H. J. (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 115, 2223-2233.
Babelova, A., Moreth, K., Tsalastra-Greul, W., Zeng-Brouwers, J., Eickelberg, O., Young, M. F., Bruckner, P., Pfeilschifter, J., Schaefer, R. M., Gröne, H. J., Schaefer, L. (2009) Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 284, 24035-24048.
Kim, S., Takahashi, H., Lin, W. W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J. L., Karin, M. (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102-106.
Midwood, K., Sacre, S., Piccinini, A. M., Inglis, J., Trebaul, A., Chan, E., Drexler, S., Sofat, N., Kashiwagi, M., Orend, G., Brennan, F., Foxwell, B. (2009) Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat. Med. 15, 774-780.
Zhang, Q., Kang, R., Zeh H. J., Lotze, M. T., Tang, D. (2013) DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death. Autophagy 9, 451-458.
Pisetsky, D. S. (2014) The translocation of nuclear molecules during inflammation and cell death. Antioxid. Redox Signal. 20, 1117-1125.
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., Hauser, C. J. (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107.
Maeda, A., Fadeel, B. (2014) Mitochondria released by cells undergoing TNF-a-induced necroptosis act as danger signals. Cell Death Dis. 5, e1312.
Takeda, K., Akira, S. (2005) Toll-like receptors in innate immunity. Int. Immunol. 17, 1-14.
Inohara, C., Chamaillard McDonald, C., Nuñez, G. (2005) NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 74, 355-383.
Akira, S., Takeda, K. (2004) Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511.
Sato, S., Sugiyama, M., Yamamoto, M., Watanabe, Y., Kawai, T., Takeda, K., Akira, S. (2003) Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171, 4304-4310.
Kawasaki, T., Kawai, T., Akira, S. (2011) Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol. Rev. 243, 61-73.
Apostolopoulos, V., McKenzie, I. F. (2001) Role of the mannose receptor in the immune response. Curr. Mol. Med. 1, 469-474.
Robinson, M. J., Sancho, D., Slack, E. C., LeibundGut-Landmann, S., Reis e Sousa, C. (2006) Myeloid C-type lectins in innate immunity. Nat. Immunol. 7, 1258-1265.
Latz, E., Xiao, T. S., Stutz, A. (2013) Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397-411.
Lightfield, K. L., Persson, J., Brubaker, S. W., Witte, C. E., von Moltke, J., Dunipace, E. A., Henry, T., Sun, Y. H., Cado, D., Dietrich, W. F., Monack, D. M., Tsolis, R. M., Vance, R. E. (2008) Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin. Nat. Immunol. 9, 1171-1178.
Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D. R., Latz, E., Fitzgerald, K. A. (2009) AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458, 514-518.
Fernandes-Alnemri, T., Yu, J. W., Datta, P., Wu, J., Alnemri, E. S. (2009) AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458, 509-513.
Yoneyama, M., Fujita, T. (2008) Structural mechanism of RNA recognition by the RIG-I-like receptors. Immunity 29, 178-181.
Muruve, D. A., Pétrilli, V., Zaiss, A. K., White, L. R., Clark, S. A., Ross, P. J., Parks, R. J., Tschopp, J. (2008) The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452, 103-107.
Schaefer, L. (2014) Complexity of danger: the diverse nature of damage-associated molecular patterns. J. Biol. Chem. 289, 35237-35245.
Piccinini, A. M., Midwood, K. S. (2010) DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010, pii: 672395.
Selkoe, D. J. (1999) Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 399 (6738 Suppl) A23-A31.
Bertram, L., Lill, C. M., Tanzi, R. E. (2010) The genetics of Alzheimer disease: back to the future. Neuron 68, 270-281.
Heneka, M. T., Kummer, M. P., Latz, E. (2014) Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14, 463-477.
Hardy, J., Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353-356.
Benilova, I., Karran, E., De Strooper, B. (2012) The toxic Ab oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357.
Roberson, E. D., Mucke, L. (2006) 100 Years and counting: prospects for defeating Alzheimer’s disease. Science 314, 781-784.
Hardy, J. A., Higgins, G. A. (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184-185.
Hsiao, K. (1998) Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp. Gerontol. 33, 883-889.
Webster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., Van Eldik, L. J. (2014) Using mice to model Alzheimer’s dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front. Genet. 5, 88.
Götz, J., Chen, F., van Dorpe, J., Nitsch, R. M. (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495.
Lewis, J., Dickson, D. W., Lin, W. L., Chisholm, L., Corral, A., Jones, G., Yen, S. H., Sahara, N., Skipper, L., Yager, D., Eckman, C., Hardy, J., Hutton, M., McGowan, E. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491.
Small, S. A., Duff, K. (2008) Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron 60, 534-542.
Jucker, M., Walker, L. C. (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45-51.
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., Bateman, R. J. (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330, 1774.
Wahlster, L., Arimon, M., Nasser-Ghodsi, N., Post, K. L., Serrano-Pozo, A., Uemura, K., Berezovska, O. (2013) Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer’s disease. Acta Neuropathol. 125, 187-199.
Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., Frautschy, S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G. C., Town, T., Morgan, D., Shinohara, M. L., Perry, V. H., Holmes, C., Bazan, N. G., Brooks, D. J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C. A., Breitner, J. C., Cole, G. M., Golenbock, D. T., Kummer, M. P. (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14, 388-405.
Heneka, M. T., Golenbock, D. T., Latz, E. (2015) Innate immunity in Alzheimer’s disease. Nat. Immunol. 16, 229-236.
Salminen, A., Ojala, J., Kauppinen, A., Kaarniranta, K., Suuronen, T. (2009) Inflammation in Alzheimer’s disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 87, 181-194.
Heneka, M. T., O’Banion, M. K. (2007) Inflammatory processes in Alzheimer’s disease. J. Neuroimmunol. 184, 69-91.
McGeer, E. G., McGeer, P. L. (2003) Inflammatory processes in Alzheimer’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 741-749.
Wyss-Coray, T. (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005-1015.
Hoozemans, J. J., Veerhuis, R., Rozemuller, J. M., Eikelenboom, P. (2006) Neuroinflammation and regeneration in the early stages of Alzheimer’s disease pathology. Int. J. Dev. Neurosci. 24, 157-165.
Klesney-Tait, J., Turnbull, I. R., Colonna, M. (2006) The TREM receptor family and signal integration. Nat. Immunol. 7, 1266-1273.
Netea, M. G., Azam, T., Ferwerda, G., Girardin, S. E., Kim, S. H., Dinarello, C. A. (2006) Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors. J. Leukoc. Biol. 80, 1454-1461.
Takahashi, K., Rochford, C. D., Neumann, H. (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 201, 647-657.
Frank, S., Burbach, G. J., Bonin, M., Walter, M., Streit, W., Bechmann, I., Deller, T. (2008) TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56, 1438-1447.
Buxbaum, J. D., Thinakaran, G., Koliatsos, V., O’Callahan, J., Slunt, H. H., Price, D. L., Sisodia, S. S. (1998) Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J. Neurosci. 18, 9629-9637.
Epstein, E. A., Chapman, M. R. (2008) Polymerizing the fibre between bacteria and host cells: the biogenesis of functional amyloid fibres. Cell. Microbiol. 10, 1413-1420.
Chapman, M. R., Robinson, L. S., Pinkner, J. S., Roth, R., Heuser, J., Hammar, M., Normark, S., Hultgren, S. J. (2002) Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 295, 851-855.
Kielian, T. (2006) Toll-like receptors in central nervous system glial inflammation and homeostasis. J. Neurosci. Res. 83, 711-730.
Falsig, J., van Beek, J., Hermann, C., Leist, M. (2008) Molecular basis for detection of invading pathogens in the brain. J. Neurosci. Res. 86, 1434-1447.
Stewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., Lacy-Hulbert, A., El Khoury, J., Golenbock, D. T., Moore, K. J. (2010) CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11, 155-161.
Fassbender, K., Walter, S., Kühl, S., Landmann, R., Ishii, K., Bertsch, T., Stalder, A. K., Muehlhauser, F., Liu, Y., Ulmer, A. J., Rivest, S., Lentschat, A., Gulbins, E., Jucker, M., Staufenbiel, M., Brechtel, K., Walter, J., Multhaup, G., Penke, B., Adachi, Y., Hartmann, T., Beyreuther, K. (2004) The LPS receptor (CD14) links innate immunity with Alzheimer’s disease. FASEB J. 18, 203-205.
Walter, S., Letiembre, M., Liu, Y., Heine, H., Penke, B., Hao, W., Bode, B., Manietta, N., Walter, J., Schulz-Schuffer, W., Fassbender, K. (2007) Role of the Toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell. Physiol. Biochem. 20, 947-956.
Liu, S., Liu, Y., Hao, W., Wolf, L., Kiliaan, A. J., Penke, B., Rübe, C. E., Walter, J., Heneka, M. T., Hartmann, T., Menger, M. D., Fassbender, K. (2012) TLR2 is a primary receptor for Alzheimer’s amyloid b peptide to trigger neuroinflammatory activation. J. Immunol. 188, 1098-1107.
Scholtzova, H., Kascsak, R. J., Bates, K. A., Boutajangout, A., Kerr, D. J., Meeker, H. C., Mehta, P. D., Spinner, D. S., Wisniewski, T. (2009) Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer’s disease-related pathology. J. Neurosci. 29, 1846-1854.
Scholtzova, H., Chianchiano, P., Pan, J., Sun, Y., Goñi, F., Mehta, P. D., Wisniewski, T. (2014) Amyloid b and tau Alzheimer’s disease related pathology is reduced by Toll-like receptor 9 stimulation. Acta Neuropathol. Commun. 2, 101.
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., Golenbock, D. T. (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9, 857-865.
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T. C., Gelpi, E., Halle, A., Korte, M., Latz, E., Golenbock, D. T. (2013) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 493, 674-678.
Muñoz-Planillo, R., Kuffa, P., Martínez-Colón, G., Smith, B. L., Rajendiran, T. M., Núñez, G. (2013) K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142-1153.
Pétrilli, V., Dostert, C., Muruve, D. A., Tschopp, J. (2007) The inflammasome: a danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 19, 615-622.
Fernandes-Alnemri, T., Wu, J., Yu, J. W., Datta, P., Miller, B., Jankowski, W., Rosenberg, S., Zhang, J., Alnemri, E. S. (2007) The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 14, 1590-1604.
Furukawa, K., Barger, S. W., Blalock, E. M., Mattson, M. P. (1996) Activation of K+ channels and suppression of neuronal activity by secreted beta-amyloid-precursor protein. Nature 379, 74-78.
Brooke, R. E., Atkinson, L., Batten, T. F., Deuchars, S. A., Deuchars, J. (2004) Association of potassium channel Kv3.4 subunits with pre-and post-synaptic structures in brainstem and spinal cord. Neuroscience 126, 1001-1010.
Pannaccione, A., Boscia, F., Scorziello, A., Adornetto, A., Castaldo, P., Sirabella, R., Taglialatela, M., Di Renzo, G. F., Annunziato, L. (2007) Up-regulation and increased activity of KV3.4 channels and their accessory subunit MinK-related peptide 2 induced by amyloid peptide are involved in apoptotic neuronal death. Mol. Pharmacol. 72, 665-673.
Fang, P., Schachner, M., Shen, Y. Q. (2012) HMGB1 in development and diseases of the central nervous system. Mol. Neurobiol. 45, 499-506.
Landsman, D., Bustin, M. (1993) A signature for the HMG-1 box DNAbinding proteins. BioEssays 15, 539-546.
Magna, M., Pisetsky, D. S. (2014) The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol. Med. 20, 138-146.
Scaffidi, P., Misteli, T., Bianchi, M. E. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195.
Müller, S., Scaffidi, P., Degryse, B., Bonaldi, T., Ronfani, L., Agresti, A., Beltrame, M., Bianchi, M. E. (2001) New EMBO members’ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20, 4337-4340.
Erlandsson Harris, H., Andersson, U. (2004) Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur. J. Immunol. 34, 1503-1512.
Castellani, P., Balza, E., Rubartelli, A. (2014) Inflammation, DAMPs, tumor development, and progression: a vicious circle orchestrated by redox signaling. Antioxid. Redox Signal. 20, 1086-1097.
Degryse, B., Bonaldi, T., Scaffidi, P., Müller, S., Resnati, M., Sanvito, F., Arrigoni, G., Bianchi, M. E. (2001) The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell Biol. 152, 1197-1206.
Yang, H., Lundbäck, P., Ottosson, L., Erlandsson-Harris, H., Venereau, E., Bianchi, M. E., Al-Abed, Y., Andersson, U., Tracey, K. J., Antoine, D. J. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18, 250-259.
Yang, D., Chen, Q., Yang, H., Tracey, K. J., Bustin, M., Oppenheim, J. J. (2007) High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 81, 59-66.
Bianchi, M. E. (2009) HMGB1 loves company. J. Leukoc. Biol. 86, 573-576.
Ivanov, S., Dragoi, A. M., Wang, X., Dallacosta, C., Louten, J., Musco, G., Sitia, G., Yap, G. S., Wan, Y., Biron, C. A., Bianchi, M. E., Wang, H., Chu, W. M. (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110, 1970-1981.
Urbonaviciute, V., Fürnrohr, B. G., Meister, S., Munoz, L., Heyder, P., De Marchis, F., Bianchi, M. E., Kirschning, C., Wagner, H., Manfredi, A. A., Kalden, J. R., Schett, G., Rovere-Querini, P., Herrmann, M., Voll, R. E. (2008) Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205, 3007-3018.
Huttunen, H. J., Fages, C., Rauvala, H. (1999) Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 274, 19919-19924.
Tian, J., Avalos, A. M., Mao, S. Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., Hua, J., An, L. L., Audoly, L., La Rosa, G., Bierhaus, A., Naworth, P., Marshak-Rothstein, A., Crow, M. K., Fitzgerald, K. A., Latz, E., Kiener, P. A., Coyle, A. J. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8, 487-496.
Kim, S., Kim, S. Y., Pribis, J. P., Lotze, M., Mollen, K. P., Shapiro, R., Loughran, P., Scott, M. J., Billiar, T. R. (2013) Signaling of high mobility group box 1 (HMGB1) through Toll-like receptor 4 in macrophages requires CD14. Mol. Med. 19, 88-98.
Takata, K., Kitamura, Y., Kakimura, J., Shibagaki, K., Tsuchiya, D., Taniguchi, T., Smith, M. A., Perry, G., Shimohama, S. (2003) Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis. Biochem. Biophys. Res. Commun. 301, 699-703.
Takata, K., Kitamura, Y., Tsuchiya, D., Kawasaki, T., Taniguchi, T., Shimohama, S. (2004) High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. J. Neurosci. Res. 78, 880-891.
Mazarati, A., Maroso, M., Iori, V., Vezzani, A., Carli, M. (2011) Highmobility group box-1 impairs memory in mice through both Toll-like receptor 4 and receptor for advanced glycation end products. Exp. Neurol. 232, 143-148.
Jang, A., Liew, H., Kim, Y. M., Choi, H., Kim, S., Lee, S. H., Ohshima, T., Mikoshiba, K., Suh, Y. H. (2013) p35 deficiency accelerates HMGB-1-mediated neuronal death in the early stages of an Alzheimer’s disease mouse model. Curr. Alzheimer Res. 10, 829-843.
Deloulme, J. C., Mbele, G. O., Baudier, J. (2002) S100 proteins. From purification to functions. Methods Mol. Biol. 172, 185-198.
Donato, R., Cannon, B. R., Sorci, G., Riuzzi, F., Hsu, K., Weber, D. J., Geczy, C. L. (2013) Functions of S100 proteins. Curr. Mol. Med. 13, 24-57.
Schäfer, B. W., Heizmann, C. W. (1996) The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem. Sci. 21, 134-140.
Donato, R., Sorci, G., Riuzzi, F., Arcuri, C., Bianchi, R., Brozzi, F., Tubaro, C., Giambanco, I. (2009) S100B’s double life: intracellular regulator and extracellular signal. Biochim. Biophys. Acta 1793, 1008-1022.
Van Eldik, L. J., Wainwright, M. S. (2003) The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor. Neurol. Neurosci. 21, 97-108.
Van Eldik, L. J., Griffin, W. S. (1994) S100 beta expression in Alzheimer’s disease: relation to neuropathology in brain regions. Biochim. Biophys. Acta 1223, 398-403.
Chaves, M. L., Camozzato, A. L., Ferreira, E. D., Piazenski, I., Kochhann, R., Dall’Igna, O., Mazzini, G. S., Souza, D. O., Portela, L. V. (2010) Serum levels of S100B and NSE proteins in Alzheimer’s disease patients. J. Neuroinflammation 7, 6.
Nishiyama, H., Knopfel, T., Endo, S., Itohara, S. (2002) Glial protein S100B modulates long-term neuronal synaptic plasticity. Proc. Natl. Acad. Sci. USA 99, 4037-4042.
Roltsch, E., Holcomb, L., Young, K. A., Marks, A., Zimmer, D. B. (2010) PSAPP mice exhibit regionally selective reductions in gliosis and plaque deposition in response to S100B ablation. J. Neuroinflammation 7, 78.
Mori, T., Town, T., Tan, J., Yada, N., Horikoshi, Y., Yamamoto, J., Shimoda, T., Kamanaka, Y., Tateishi, N., Asano, T. (2006) Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J. Pharmacol. Exp. Ther. 318, 571-578.
Mori, T., Koyama, N., Arendash, G. W., Horikoshi-Sakuraba, Y., Tan, J., Town, T. (2010) Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer’s disease. Glia 58, 300-314.
Abe, M., Umehara, F., Kubota, R., Moritoyo, T., Izumo, S., Osame, M. (1999) Activation of macrophages/microglia with the calcium-binding proteins MRP14 and MRP8 is related to the lesional activities in the spinal cord of HTLV-I associated myelopathy. J. Neurol. 246, 358-364.
Shepherd, C. E., Goyette, J., Utter, V., Rahimi, F., Yang, Z., Geczy, C. L., Halliday, G. M. (2006) Inflammatory S100A9 and S100A12 proteins in Alzheimer’s disease. Neurobiol. Aging 27, 1554-1563.
Ha, T. Y., Chang, K. A., Kim, Ja., Kim, H. S., Kim, S., Chong, Y. H., Suh, Y. H. (2010) S100a9 knockdown decreases the memory impairment and the neuropathology in Tg2576 mice, AD animal model. PLoS One 5, e8840.
Hermani, A., De Servi, B., Medunjanin, S., Tessier, P. A., Mayer, D. (2006) S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp. Cell Res. 312, 184-197.
Zimmer, D. B., Cornwall, E. H., Reynolds, P. D., Donald, C. M. (1998) S100A1 regulates neurite organization, tubulin levels, and proliferation in PC12 cells. J. Biol. Chem. 273, 4705-4711.
Kummer, M. P., Vogl, T., Axt, D., Griep, A., Vieira-Saecker, A., Jessen, F., Gelpi, E., Roth, J., Heneka, M. T. (2012) Mrp14 deficiency ameliorates amyloid b burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing. J. Neurosci. 32, 17824-17829.
Bartolomucci, A., Possenti, R., Mahata, S. K., Fischer-Colbrie, R., Loh, Y. P., Salton, S. R. (2011) The extended granin family: structure, function, and biomedical implications. Endocr. Rev. 32, 755-797.
Lassmann, H., Weiler, R., Fischer, P., Bancher, C., Jellinger, K., Floor, E., Danielczyk, W., Seitelberger, F., Winkler, H. (1992) Synaptic pathology in Alzheimer’s disease: immunological data for markers of synaptic and large dense-core vesicles. Neuroscience 46, 1-8.
Yasuhara, O., Kawamata, T., Aimi, Y., McGeer, E. G., McGeer, P. L. (1994) Two types of dystrophic neurites in senile plaques of Alzheimer disease and elderly non-demented cases. Neurosci. Lett. 171, 73-76.
Munoz, D. G. (1991) Chromogranin A-like immunoreactive neurites are major constituents of senile plaques. Lab. Invest. 64, 826-832.
Taupenot, L., Ciesielski-Treska, J., Ulrich, G., Chasserot-Golaz, S., Aunis, D., Bader, M. F. (1996) Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience 72, 377-389.
Taylor, D. L., Diemel, L. T., Cuzner, M. L., Pocock, J. M. (2002) Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer’s disease. J. Neurochem. 82, 1179-1191.
Terada, K., Yamada, J., Hayashi, Y., Wu, Z., Uchiyama, Y., Peters, C., Nakanishi, H. (2010) Involvement of cathepsin B in the processing and secretion of interleukin-1beta in chromogranin A-stimulated microglia. Glia 58, 114-124.
Huttunen, H. J., Kuja-Panula, J., Rauvala, H. (2002) Receptor for advanced glycation end products (RAGE) signaling induces CREBdependent chromogranin expression during neuronal differentiation. J. Biol. Chem. 277, 38635-38646.
Lechner, T., Adlassnig, C., Humpel, C., Kaufmann, W. A., Maier, H., Reinstadler-Kramer, K., Hinterhölzl, J., Mahata, S. K., Jellinger, K. A., Marksteiner, J. (2004) Chromogranin peptides in Alzheimer’s disease. Exp. Gerontol. 39, 101-113.
Jylhävä, J., Kotipelto, T., Raitala, A., Jylhä, M., Hervonen, A., Hurme, M. (2011) Aging is associated with quantitative and qualitative changes in circulating cell-free DNA: the Vitality 90+ study. Mech. Ageing Dev. 132, 20-26.
Jylhävä, J., Jylhä, M., Lehtimäki, T., Hervonen, A., Hurme, M. (2012) Circulating cell-free DNA is associated with mortality and inflammatory markers in nonagenarians: the Vitality 90+ study. Exp. Gerontol. 47, 372-378.
Hauser, C. J., Sursal, T., Rodriguez, E. K., Appleton, P. T., Zhang, Q., Itagaki, K. (2010) Mitochondrial damage associated molecular patterns from femoral reamings activate neutrophils through formyl peptide receptors and P44/42 MAP kinase. J. Orthop. Trauma 24, 534-538.
Zhang, Q., Itagaki, K., Hauser, C. J. (2010) Mitochondrial DNA is released by shock and activates neutrophils via p38 MAP kinase. Shock 34, 55-59.
Mecocci, P., MacGarvey, U., Beal, M. F. (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann. Neurol. 36, 747-751.
De la Monte, S. M., Luong, T., Neely, T. R., Robinson, D., Wands, J. R. (2000) Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer’s disease. Lab. Invest. 80, 1323-1335.
Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., Xu, H. W., Stern, D., McKhann, G., Yan, S. D. (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J. 19, 2040-2041.
Lin, M. T., Beal, M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795.
Castellani, R., Hirai, K., Aliev, G., Drew, K. L., Nunomura, A., Takeda, A., Cash, A. D., Obrenovich, M. E., Perry, G., Smith, M. A. (2002) Role of mitochondrial dysfunction in Alzheimer’s disease. J. Neurosci. Res. 70, 357-360.
Tamagno, E., Parola, M., Bardini, P., Piccini, A., Borghi, R., Guglielmotto, M., Santoro, G., Davit, A., Danni, O., Smith, M. A., Perry, G., Tabaton, M. (2005) Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 92, 628-636.
Lovell, M. A., Xiong, S., Xie, C., Davies, P., Markesbery, W. R. (2004) Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J. Alzheimers Dis. 6, 659-671, discussion 673-681.
Barbalat, R., Ewald, S. E., Mouchess, M. L., Barton, G. M. (2011) Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185-214.
Rathinam, V. A., Jiang, Z., Waggoner, S. N., Sharma, S., Cole, L. E., Waggoner, L., Vanaja, S. K., Monks, B. G., Ganesan, S., Latz, E., Hornung, V., Vogel, S. N., Szomolanyi-Tsuda, E., Fitzgerald, K. A. (2010) The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 11, 395-402.
Stetler, R. A., Gan, Y., Zhang, W., Liou, A. K., Gao, Y., Cao, G., Chen, J. (2010) Heat shock proteins: cellular and molecular mechanisms in the central nervous system. Prog. Neurobiol. 92, 184-211.
Meriin, A. B., Sherman, M. Y. (2005) Role of molecular chaperones in neurodegenerative disorders. Int. J. Hyperthermia 21, 403-419.
Srivastava, P. (2002) Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2, 185-194.
Basu, S., Binder, R. J., Suto, R., Anderson, K. M., Srivastava, P. K. (2000) Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 12, 1539-1546.
Asea, A., Rehli, M., Kabingu, E., Boch, J. A., Bare, O., Auron, P. E., Stevenson, M. A., Calderwood, S. K. (2002) Novel signal transduction pathway utilized by extracellular HSP70: role of Toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem. 277, 15028-15034.
Luong, M., Zhang, Y., Chamberlain, T., Zhou, T., Wright, J. F., Dower, K., Hall, J. P. (2012) Stimulation of TLR4 by recombinant HSP70 requires structural integrity of the HSP70 protein itself. J. Inflamm. (Lond.) 9, 11.
Ran, R., Lu, A., Zhang, L., Tang, Y., Zhu, H., Xu, H., Feng, Y., Han, C., Zhou, G., Rigby, A. C., Sharp, F. R. (2004) Hsp70 promotes TNFmediated apoptosis by binding IKK gamma and impairing NF-kappa B survival signaling. Genes Dev. 18, 1466-1481.
Li, Z., Menoret, A., Srivastava, P. (2002) Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr. Opin. Immunol. 14, 45-51.
Wang, Y., Kelly, C. G., Singh, M., McGowan, E. G., Carrara, A. S., Bergmeier, L. A., Lehner, T. (2002) Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. J. Immunol. 169, 2422-2429.
Asea, A., Kraeft, S. K., Kurt-Jones, E. A., Stevenson, M. A., Chen, L. B., Finberg, R. W., Koo, G. C., Calderwood, S. K. (2000) HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6, 435-442.
Van Noort, J. M. (2008) Stress proteins in CNS inflammation. J. Pathol. 214, 267-275.
Evans, C. G., Wisén, S., Gestwicki, J. E. (2006) Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J. Biol. Chem. 281, 33182-33191.
Magrané, J., Smith, R. C., Walsh, K., Querfurth, H. W. (2004) Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J. Neurosci. 24, 1700-1706.
Dou, F., Netzer, W. J., Tanemura, K., Li, F., Hartl, F. U., Takashima, A., Gouras, G. K., Greengard, P., Xu, H. (2003) Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. USA 100, 721-726.
Peterson, L. B., Blagg, B. S. (2009) To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med. Chem. 1, 267-283.
Takata, K., Kitamura, Y., Tsuchiya, D., Kawasaki, T., Taniguchi, T., Shimohama, S. (2003) Heat shock protein-90-induced microglial clearance of exogenous amyloid-beta1-42 in rat hippocampus in vivo. Neurosci. Lett. 344, 87-90.
Doyle, S. M., Genest, O., Wickner, S. (2013) Protein rescue from aggregates by powerful molecular chaperone machines. Nat. Rev. Mol. Cell Biol. 14, 617-629.
Lu, R. C., Tan, M. S., Wang, H., Xie, A. M., Yu, J. T., Tan, L. (2014) Heat shock protein 70 in Alzheimer’s disease. BioMed Res. Int. 2014, 435203.
Veereshwarayya, V., Kumar, P., Rosen, K. M., Mestril, R., Querfurth, H. W. (2006) Differential effects of mitochondrial heat shock protein 60 and related molecular chaperones to prevent intracellular beta-amyloidinduced inhibition of complex IV and limit apoptosis. J. Biol. Chem. 281, 29468-29478.
Gilchrist, M., Thorsson, V., Li, B., Rust, A. G., Korb, M., Roach, J. C., Kennedy, K., Hai, T., Bolouri, H., Aderem, A. (2006) Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 441, 173-178.
Py, B. F., Kim, M. S., Vakifahmetoglu-Norberg, H., Yuan, J. (2013) Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 49, 331-338.
Ben-Menachem-Zidon, O., Ben-Menahem, Y., Ben-Hur, T., Yirmiya, R. (2014) Intra-hippocampal transplantation of neural precursor cells with transgenic over-expression of IL-1 receptor antagonist rescues memory and neurogenesis impairments in an Alzheimer’s disease model. Neuropsychopharmacology 39, 401-414.
Oprica, M., Hjorth, E., Spulber, S., Popescu, B. O., Ankarcrona, M., Winblad, B., Schultzberg, M. (2007) Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1 receptor antagonist. J. Cell. Mol. Med. 11, 810-825.